Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response.
Ladislav PazderaJoshua M CohenXiaoping NingVerena Ramirez CamposRonghua YangPatricia Pozo-RosichPublished in: Cephalalgia : an international journal of headache (2021)
Significant improvements in efficacy were observed with fremanezumab compared with placebo, even in patients who had previously experienced inadequate response to 4 different classes of migraine preventive medications.ClinicalTrials.gov identifier: NCT03308968.